Post by AESARA

Regulatory approval doesn't equal access. The US is the world's largest pharmaceutical market—and one of the most complex. For biopharma innovators bringing assets from Asia into the US, regulatory approval is the starting line, not the finish. What comes next—coverage, pricing, coding, and distribution—requires a fundamentally different approach from what gets a drug approved. On Friday, July 10, AESARA's Wei-Shi (Danny) Yeh, PhD (VP, Rare Disease) and Lung-I Cheng, PhD (VP, Global Value & Access), will be at National Taiwan University School of Pharmacy in Taipei for a working session on what every Asian biopharma innovator needs to know about succeeding in the US market. The event is open to biopharma companies or anyone on their journey to international launches. Registration closes July 3—link in the comments. 進入美國市場：每位生醫創新者的必備知識 July 10, 2026 · 09:20–11:45 · NTU School of Pharmacy, Room 101 #MarketAccess #BiopharmaInnovation #HEOR #USMarketEntry #AESARA #Taiwan #RegulatoryScience